Current Value
$281.021 Year Return
Current Value
$281.021 Year Return
Double maintains 8 strategies that include ALNY - Alnylam Pharmaceuticals, Inc.
Name | Correlation | AUM | Expense Ratio |
---|---|---|---|
TAIL | -26.78% | $140.49M | 0.59% |
VIXY | -25.06% | $109.64M | 0.85% |
TPMN | -19.02% | $31.54M | 0.65% |
BTAL | -17.21% | $361.41M | 1.43% |
CLIP | -12.71% | $1.50B | 0.07% |
SHYM | -12.53% | $322.93M | 0.35% |
IVOL | -12.15% | $353.94M | 1.02% |
TBLL | -8.15% | $2.46B | 0.08% |
GBIL | -8.13% | $6.17B | 0.12% |
BIL | -7.64% | $45.95B | 0.1356% |
BILZ | -7.62% | $876.85M | 0.14% |
BSMW | -7.57% | $102.62M | 0.18% |
GSST | -6.88% | $857.21M | 0.16% |
FXY | -6.84% | $838.61M | 0.4% |
TFLO | -5.56% | $7.06B | 0.15% |
XHLF | -4.80% | $1.46B | 0.03% |
USFR | -4.09% | $18.91B | 0.15% |
ULST | -3.51% | $637.77M | 0.2% |
SGOV | -3.38% | $45.91B | 0.09% |
SPTS | -3.36% | $5.76B | 0.03% |
Name | Correlation | AUM | Expense Ratio |
---|---|---|---|
SHV | -0.04% | $20.94B | 0.15% |
DBA | 0.09% | $839.66M | 0.93% |
YEAR | 0.13% | $1.40B | 0.25% |
CANE | -0.23% | $10.71M | 0.29% |
SUB | 0.26% | $9.40B | 0.07% |
UTWO | -0.27% | $387.71M | 0.15% |
UUP | -0.34% | $292.27M | 0.77% |
VGSH | -0.35% | $22.38B | 0.03% |
TUR | -0.54% | $139.51M | 0.59% |
FLMI | -0.55% | $649.76M | 0.3% |
BRRR | 0.56% | $637.29M | 0.25% |
ARKB | 0.59% | $5.06B | 0.21% |
SMMU | -0.59% | $822.53M | 0.35% |
FMHI | 0.60% | $757.44M | 0.7% |
GBTC | 0.65% | $19.74B | 1.5% |
EZBC | 0.66% | $533.04M | 0.29% |
BITB | 0.66% | $4.00B | 0.2% |
HODL | 0.72% | $1.54B | 0.25% |
IBTG | -0.74% | $1.88B | 0.07% |
BTCW | 0.75% | $161.85M | 0.3% |
Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
---|---|---|---|---|
TLPH | 0.01% | $10.05M | -57.39% | 0.00% |
ZYXI | -0.02% | $66.22M | -80.09% | 0.00% |
BBDO | -0.04% | $12.93B | +12.38% | 1.50% |
PLG | 0.05% | $115.89M | -32.32% | 0.00% |
AWK | 0.05% | $27.37B | +4.54% | 2.22% |
CYRX | 0.07% | $337.42M | -50.73% | 0.00% |
ESGR | 0.08% | $4.98B | +8.17% | 0.00% |
CCEC | 0.10% | $1.02B | +3.91% | 2.71% |
FIZZ | 0.13% | $4.16B | +0.40% | 0.00% |
TH | -0.14% | $690.70M | -39.27% | 0.00% |
EB | 0.18% | $222.46M | -56.80% | 0.00% |
GHG | 0.23% | $138.86M | -32.90% | 0.00% |
JKS | 0.28% | $972.90M | -21.70% | 0.00% |
BPT | 0.30% | $13.70M | -73.66% | 0.00% |
WDFC | -0.34% | $3.30B | +2.13% | 1.49% |
PLYA | -0.34% | $1.65B | +57.38% | 0.00% |
APT | 0.38% | $48.89M | -8.91% | 0.00% |
API | 0.42% | $257.04M | +17.29% | 0.00% |
FARO | 0.43% | $812.11M | +115.84% | 0.00% |
ANF | 0.46% | $3.79B | -41.29% | 0.00% |
Name | Correlation | AUM | Expense Ratio |
---|---|---|---|
BBH | 53.99% | $327.42M | 0.35% |
FBT | 53.00% | $994.71M | 0.56% |
IBB | 50.68% | $5.22B | 0.45% |
PBE | 48.12% | $214.12M | 0.58% |
XBI | 47.14% | $4.85B | 0.35% |
FHLC | 46.51% | $2.42B | 0.084% |
VHT | 46.00% | $14.92B | 0.09% |
IYH | 45.96% | $2.78B | 0.39% |
GNOM | 44.87% | $40.65M | 0.5% |
FXH | 44.39% | $891.82M | 0.62% |
PINK | 44.08% | $131.52M | 0.5% |
IXJ | 44.01% | $3.78B | 0.41% |
XLV | 43.64% | $34.49B | 0.09% |
IHE | 43.25% | $550.13M | 0.39% |
XPH | 41.95% | $136.58M | 0.35% |
RSPA | 41.68% | $319.03M | 0.29% |
PPH | 41.53% | $626.20M | 0.36% |
QQA | 40.47% | $225.66M | 0.29% |
PTH | 39.34% | $96.56M | 0.6% |
RSPH | 38.22% | $754.08M | 0.4% |
Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
---|---|---|---|---|
IONS | 55.17% | $5.25B | -12.31% | 0.00% |
ARGX | 49.21% | $34.30B | +49.16% | 0.00% |
RXO | 38.64% | $2.80B | -19.21% | 0.00% |
AMGN | 36.95% | $146.09B | -13.67% | 3.40% |
REGN | 36.22% | $63.16B | -39.57% | 0.00% |
AMWL | 36.00% | $118.26M | -23.08% | 0.00% |
LLY | 34.95% | $694.97B | -4.91% | 0.73% |
DHR | 33.98% | $136.66B | -27.90% | 0.60% |
A | 33.89% | $32.05B | -27.16% | 0.87% |
ARWR | 33.87% | $2.12B | -38.64% | 0.00% |
NBIX | 33.85% | $11.90B | -15.25% | 0.00% |
LH | 33.68% | $20.61B | +15.55% | 1.17% |
SPGI | 33.52% | $159.26B | +18.55% | 0.71% |
TMO | 33.46% | $152.86B | -32.19% | 0.40% |
MCO | 33.44% | $87.67B | +18.28% | 0.72% |
TECH | 33.21% | $7.56B | -41.77% | 0.49% |
MORN | 33.13% | $13.10B | +3.36% | 0.56% |
META | 32.45% | $1.62T | +36.06% | 0.32% |
BIP | 32.32% | $14.99B | +6.59% | 5.08% |
MEDP | 32.27% | $8.52B | -24.63% | 0.00% |
Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
---|---|---|---|---|
SEG | -20.08% | $239.93M | -26.61% | 0.00% |
HEES | -10.33% | $3.52B | +99.54% | 1.15% |
FMTO | -10.08% | $45.74M | -99.96% | 0.00% |
CBOE | -9.62% | $22.95B | +20.67% | 1.12% |
UUU | -9.03% | $4.93M | +40.20% | 0.00% |
CMTL | -7.47% | $50.48M | -14.43% | 0.00% |
VSTA | -6.78% | $326.82M | +11.64% | 0.00% |
IRBT | -6.60% | $86.16M | -75.28% | 0.00% |
GORV | -6.50% | $15.42M | -96.17% | 0.00% |
VSA | -6.33% | $7.04M | -49.24% | 0.00% |
AIFU | -6.15% | $9.85M | -95.03% | 0.00% |
MPAA | -6.10% | $212.48M | +117.00% | 0.00% |
CARV | -5.79% | $7.41M | -22.87% | 0.00% |
CODX | -5.41% | $10.29M | -73.23% | 0.00% |
RMD | -4.91% | $36.45B | +13.01% | 0.85% |
LFVN | -4.81% | $158.74M | +75.02% | 1.27% |
ALDX | -4.75% | $129.37M | -47.19% | 0.00% |
INSP | -4.63% | $4.41B | -5.87% | 0.00% |
PLL | -4.24% | $146.82M | -56.22% | 0.00% |
BTCT | -4.11% | $25.35M | +93.08% | 0.00% |
SeekingAlpha
BlackRock Health Sciences Term Trust's discount to NAV has narrowed sharply, eroding the original deep-value thesis. See why BMEZ is a Sell.
Yahoo
CAMBRIDGE, Mass., May 17, 2025--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today presented the most contemporary analysis of the HELIOS-B Phase 3 study of vutrisiran for the treatment of ATTR amyloidosis with cardiomyopathy (ATTR-CM) as a late-breaking abstract at the Heart Failure 2025 Congress, a scientific congress of the European Society of Cardiology, taking place May 17-20 in Belgrade, Serbia. The results demonstrate that vutrisiran, which rapidly
Yahoo
The United States market has shown robust performance with a 4.5% rise over the last week and an 11% increase in the past year, supported by an anticipated annual earnings growth of 14%. In this favorable environment, identifying high growth tech stocks that align with these positive trends can be key to capitalizing on potential opportunities.
Finnhub
Part II of the mRNA patent wars series highlights a rapidly intensifying wave of litigation as biotech companies, academic institutions, and pharmaceutical giants assert competing claims over...
Yahoo
We recently compiled a list of the 12 Best Growth Stocks to Buy and Hold for the Long Term. In this article, we are going to take a look at where Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) stands against the other growth stocks. What’s the Bull Case for US Equities? The market closed last week mostly lower, however, […]
Yahoo
In May 2025, Alnylam Pharmaceuticals (NasdaqGS:ALNY) announced its plan to present new data from its transthyretin amyloidosis (TTR) franchise at the Heart Failure 2025 Congress, alongside securing broader international approvals for its therapeutic vutrisiran (AMVUTTRA). During the same month, the overall market rallied due to positive developments in U.S.-China trade relations, with major indexes experiencing substantial gains. Alnylam's 5.63% rise over the period likely reflects investor...